Navigation Links
Nventa updates progress of cervical dysplasia trial with new HspE7
Date:10/18/2007

-- Company Completes Enrollment in First Cohort --

SAN DIEGO, CA, Oct. 18 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced that the Company has completed enrollment of the first cohort in its Phase 1 clinical trial to assess the safety and tolerability of new HspE7 in patients with cervical intraepithelial neoplasia (CIN).

The trial is expected to dose up to 5 cohorts comprising twenty-four patients. Four cohorts will be administered 500 mcg of HspE7 and doses of 50, 500, 1,000, or 2,000 mcg of adjuvant containing Poly-IC, a toll-like receptor-3 (or TLR3) agonist. An additional cohort of six patients administered 1,000 mcg of HspE7 and 2,000 mcg of adjuvant may be added if deemed appropriate based on data from the previous four cohorts.

In addition to safety and tolerability assessment, Nventa will also collect immunological data from these patients at the end of each cohort that may provide an early indication of potential efficacy of the compound. All patients will be typed for class I and II human leukocyte antigen (HLA) subtypes, and will be evaluated for cytokine responses, anti-HspE7 antibodies and cellular (T-cell) immunology.

Affiliations and investigators in this trial currently include the Montefiore Medical Center; William D. Kolton, M.D. of San Diego, California; Linda Roman, M.D. of the University of Southern California (USC); Michael L. Twede, M.D. of the Salt Lake Women's Center in Sandy, Utah; and Mark T. Saunders, M.D. at the Mt. Timpanogos Women's Healthcare/Physician's Research in Pleasant Grove, Utah.

Following successful completion of this Phase 1 trial, the Company anticipates launching a Phase 2 clinical trial with new HspE7 in patients with high-grade cervical intraepithelial neoplasia (CIN 2/3). The Company is also in discussions with clinical investigators regarding the design and implementation of a second Phase 2 trial with new HspE7 in patients that ar
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Merge announces sofware updates, upcoming acquisition
2. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
3. Solinus updates MailFoundry anti-spam hardware, switching to Linux
4. Wingra Technologies updates data migration software
5. Wisconsin cities make progress on wireless Internet coverage
6. Doyle laments lack of progress on stem cell bill
7. U.S. health system could undermine EHR progress
8. Stem-cell controversies slow progress
9. VC trends, company progress discussed at Mason Wells portfolio meeting
10. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
11. Furious pace of Midwest biotech events marks progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 BioHealth Innovation, Inc. (BHI), ... innovations and increasing access to early-stage funding in ... capitalist, Tania Fernandez , Ph.D., has joined the ... be a member of the management team for a ... $50 million in seed and early-stage equity investments to ...
(Date:9/30/2014)... September 30, 2014 The custom stainless ... Boston Product Show 2014. The Boston Area Chapter of ... 23rd annual, day-long event for Wed., Oct. 1 at ... to be the largest in ISPE Boston’s long history, ... of 3,000 attendees expected. , HOLLOWAY AMERICA President ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an ... of a session that he will lead on “Stem Cells” ... February 17-18, 2015 in London. In the interview posted ... Sherley to respond to several questions on the current state ... stem cell toxicity, and future trends in the use of ...
(Date:9/30/2014)... Pittsburgh PA (PRWEB) September 30, 2014 ... Nurses ( IACRN), a non-profit organization based ... Clinical Research Excellence and Safety (ACRES), a ... of a strategic alliance agreement, setting the stage ... is to enhance clinical research quality and safety ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... Mednet, SWOG Will Enhance Quality and Speed Image Transfer at ... Cost While Ensuring 21 CFR Part 11 ... largest,diagnostic imaging network, today announced it has been selected by,Southwest ... trials cooperative groups in the United States, to provide a,secure, ...
... 17 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today ... company,s Board of Directors. Mr. Turner brings over 25 ... also serve on,the company,s audit committee., "We are ... Christopher S.,Henney, Chairman of the Board of Directors of ...
... Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced ... of Directors. Dr. Durrant is currently,Worldwide Vice President ... (NYSE: JNJ )., "ANAVEX is both ... our,Board," said Dr. Kontzalis, Chief Executive Officer for ...
Cached Biology Technology:AG Mednet to Provide Image Network for Southwest Oncology Group 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3Anavex strengthens Board of Directors 2Anavex strengthens Board of Directors 3
(Date:9/30/2014)... JOLLAJoseph Ecker, a Salk professor and Howard Hughes ... scientist, have been named recipients in the 2014 ... Health (NIH) through the BRAIN (Brain Research through ... neuroscience. The grant, announced September 30, provides more ... scientists over three years. , The BRAIN Initiative, ...
(Date:9/30/2014)... . FRANKFURT. Truffles, ... the world. Because they grow underground, people use trained dogs ... truffles is not only of interest to gourmets. A group ... Goethe University Frankfurt have discovered that the smell of white ... inside truffle fruiting bodies. , White truffles from the Piedmont ...
(Date:9/30/2014)... trouble getting pregnanteven with IVF? Here,s some hope: A ... The FASEB Journal , explains how ... known as PAWP, which induced embryo development in human ... embryo development by the sperm cell during fertilization. , ... a major paradigm shift in our understanding of human ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... N.Y. Researchers at Rensselaer Polytechnic Institute have developed ... dangerous proteins such as anthrax toxin, and render them ... to the creation of new antibacterial and antimicrobial films ... holds promise for new methods of seeking out and ...
... overgrowth in the latter part of an infants first ... according to research presented today at the American College ... research which has found brain overgrowth in autistic children ... Joseph Piven, M.D., Director of the Neurodevelopmental Disorders Research ...
... unknown enzymatic mechanism that subverts the early host immune ... pathway in host cells. The research, published by Cell ... may have important implications for the food industry and ... lead to intriguing questions about whether mammalian cells can ...
Cached Biology News:Using carbon nanotubes to seek and destroy anthrax toxin and other harmful proteins 2New studies suggest brain overgrowth in 1-year-olds linked to development of autism 2Pathogens use previously undescribed mechanism to sabotage host immune system 2